1

Your cart is empty.

The Most-Trusted Regulations & Guidelines Books on the Market.

Celebrating 15 Years of Excellence.

Now Accepting Pre-orders for 2017 Books

Book 1B:  2017 FDA Good Clinical Practice Guide

Book 1B: 2017 FDA Good Clinical Practice Guide

$ 15.95

Return to Previous Page

This spiral-bound, 5" x 7.5" book is a compilation of the FDA Good Clinical Practice regulations (21 CFR Parts 11, 50, 54, 56, and 312) and ICH Guidelines (E6, E2A, and E8), as well as the FDA Information Sheets and other guidance documents that govern the conduct of clinical trials for drug research.  Please note that this book does NOT contain the sections of 21 CFR
Part 314 on New Drug Applications (NDAs).  21 CFR Part 314 is contained in its entirety in Book 1A, Selected Regulatons and Guidance for Drug Studies.

Who Uses this Book and How?
• Clinical Research staff, as job aids
• Training departments, as training handouts
• Human Resources, as part of new-employee orientation
• Legal/Regulatory/QA staff, for company-wide distribution

What's the Price?
• 1-249 copies:  $15.95             • 250-499 copies:  $14.95
• 500-749 copies: $13.95          • 750+ copies:  $12.95

Custom Cover Prices*?
• 1-24 copies:  unavailable             • 25-100 copies:  $2.00/book
• 100-249 copies: $1.00/book        • 250+ copies:  No charge

* Based on quantities of a single book title

•  Index to 21 CFR Parts 11, 50, 54, 56, 312, 314

•  CFR Title 21:  Food and Drugs (Revised as of April 2017)

11    Electronic Records/Electronic Signatures (Revised 2017)
50    Protection of Human Subjects
54    Financial Disclosure
56    Institutional Review Boards (Revised 2017)
312  Investigational New Drug Application
314  Sections 314.80, 314.81: Post-Marketing Reporting
Section 314.126: Adequate and Well-Controlled Studies (Revised 2017)

•  FDA INFORMATION SHEETS:  Guidance for IRBs, Clinical Investigators and Sponsors (Revised 2017)

Includes guidance on Informed Consent, Subject Recruitment, Payments to Study Subjects, Subject Screening Tests, and Treatment Use of Investigational Drugs.

•  ICH Guidelines (US, Step 5)

E6     Good Clinical Practice (Revised to include Version R2 Addendum)
E2A  Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
E8     General Considerations for Clinical Trials

• Additional FDA Guidance Documents:

• Selected Drug Development Web Sites (Revised 2017)
• Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring
• FDA Compliance Program Guidance #7348.810: Sponsors, CROs & Monitors
• Adverse Event Reporting to IRBs - Improving Human Subject Protection
• Safety Reporting Requirements for INDs and BA/BE Studies

• European Directives on GCP (2001 and 2005) 

Click here to see an enlarged pdf cover